Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Change in Acquisitions & Divestments (2020 - 2025)

Bolt Biotherapeutics' Change in Acquisitions & Divestments history spans 6 years, with the latest figure at $19.7 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 47.32% year-over-year to $19.7 million; the TTM value through Sep 2025 reached $85.0 million, down 49.65%, while the annual FY2024 figure was $146.3 million, 38.06% down from the prior year.
  • Change in Acquisitions & Divestments for Q3 2025 was $19.7 million at Bolt Biotherapeutics, down from $25.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $117.5 million in Q1 2022 and bottomed at $3.8 million in Q2 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $37.4 million (2024), against an average of $40.3 million.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 1870.87% in 2021 before it crashed 56.16% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $51.3 million in 2021, then decreased by 18.14% to $42.0 million in 2022, then grew by 14.29% to $48.0 million in 2023, then tumbled by 46.88% to $25.5 million in 2024, then dropped by 22.8% to $19.7 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Change in Acquisitions & Divestments are $19.7 million (Q3 2025), $25.3 million (Q2 2025), and $14.6 million (Q1 2025).